Clinical Trial: NCT03701334
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).
Official Title
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Conditions
Early Breast Cancer
Intervention / Treatment
- Drug: Ribociclib
- Other: Endocrine Therapy (ET)
Other Study ID Numbers
- CLEE011O12301C
- 2023-510357-42-00
- TRIO033
- 2023
Start Date (Actual)
2018-12-07
Primary Completion Date (Estimated)
2030-05-29
Study Completion Date (Estimated)
2030-05-29
Enrollment (Actual)
5101
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).
Official Title
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Conditions
Early Breast Cancer
Intervention / Treatment
- Drug: Ribociclib
- Other: Endocrine Therapy (ET)
Other Study ID Numbers
- CLEE011O12301C
- 2023-510357-42-00
- TRIO033
- 2023
Start Date (Actual)
2018-12-07
Primary Completion Date (Estimated)
2030-05-29
Study Completion Date (Estimated)
2030-05-29
Enrollment (Actual)
5101
Study Type
Interventional
Phase
Phase 3